GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Inventories, Other

Y-Biologics (XKRX:338840) Inventories, Other : ₩0 Mil (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Y-Biologics's other inventories for the quarter that ended in Mar. 2025 was ₩0 Mil.


Y-Biologics Inventories, Other Historical Data

The historical data trend for Y-Biologics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Inventories, Other Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Other
Get a 7-Day Free Trial - - - - -

Y-Biologics Quarterly Data
Dec17 Dec18 Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Y-Biologics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Y-Biologics Business Description

Traded in Other Exchanges
N/A
Address
B715 Daedeok Biz Center, 17 Techno 4-ro, Yuseong-gu, Daejeon, KOR, 34013
Y-Biologics Inc is a company that has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of the development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics Headlines

No Headlines